Abstract:

Tumor-associated angiogenesis is triggered by multiple angiogenic factors. Vascular endothelial growth factor blockers are currently a major mechanism of angiogenesis inhibition; however, either insensitivity due to the targeting of single angiogenic factors or serious side effects due to non-specific exposure ultimately leads to the failure of treatment. The herb-derived compound triptolide (TP) can inhibit tumor growth through multiple mechanisms. However, its hydrophobicity and side effects have hindered its translation to the clinic. Here, we have prepared TP-polymeric micelles (TP-PMs) using methoxy poly(ethylene glycol)block poly( -caprolactone). The drug loading efficiency and encapsulation efficiency can reach 7.2±0.10% and 99.1±1.05%, respectively. The TP-PM solution consisted of monodispersed particles (PDI = 0.100±0.023), which were 53.1±1.2 nm in size. In vitro release profiles indicated that the TP-PM solution exhibited 

triptolide (TP, Purity > 99%) was purchased from Chengdu Biopurify Phytochemi- cals Co, Ltd. ..